JD Supra15d
Teva v. Amneal Ruling Interprets Orange Book Listing Statute, Affirms Delisting of Device Patents
On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...
BMJ20d
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study
Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...
JD Supra23d
CAFC Decision on Orange Book Listings for Drug/Device Combination Patents
Teva holds an approved NDA for its ProAir® HFA Inhalation Aerosol product, which permits Teva to market and sell an inhaler device that administers the API albuterol sulfate. Teva listed several ...
Medscape29d
Effects of Extreme Temperatures on Drug Delivery of Albuterol Sulfate Hydrofluoroalkane Inhalation Aerosols
Cumulative propellant loss as a function of study duration for Proventil HFA and Ventolin HFA metered-dose inhalers. Albuterol dose per actuation as a function of temperature for Proventil HFA ...